Skip to content

Xencor XNCR Quick ratio

Quick ratio at other companies

Amgen logo
AmgenAMGN
+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-1.1×
Janux Therapeutics logo
Janux TherapeuticsJANX
17×-41.5×
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
13.9×+3.7×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
7.6×-0.7×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
27.8×+10.1×

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+79.8%
Enterprise value$1.23B+58.6%
P/S11×+6.3×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Calculated from Xencor’s reported figures.

Based on the most recent quarter.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's quick ratio?
Xencor (XNCR) reported quick ratio of 6.6× in Q1 2026.
How has Xencor's quick ratio changed year-over-year?
Xencor's quick ratio increased by 11.5% year-over-year, from 5.9× to 6.6×.
What is the long-term trend for Xencor's quick ratio?
Over 5 years (2020 to 2025), Xencor's quick ratio has grown at a 3.5% compound annual growth rate (CAGR), from 5.3× to 6.3×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.